On February 23, 2015, the FDA approved panobinostat (Farydak; Novartis Pharmaceuticals) for the treatment of patients with multiple myeloma. Panobinostat works by inhibiting the histone deacetylase (HDAC) enzymes, which slow and/or kill the excess production of plasma cells in the bone marrow that leads to the development of multiple myeloma.
Although the majority of patients with multiple myeloma report being involved in making decisions pertaining to their care, approximately 50% of them also believe they lack sufficient knowledge about their disease to be fully conversant with their physicians.
n patients with smoldering multiple myeloma, antitumor treatment alone (primarily with an immunomodulating agent) or in combination with bisphosphonates improves survival compared with observation alone, according to a meta-analysis of pharmacotherapy trials.
Histone deacetylase (HDAC) inhibitors may become a promising component of the treatment of multiple myeloma, based their unique mechanism of action and cytotoxic synergy with other agents. Several studies presented at the 2014 American Society of Hematology meeting evaluated the safety and efficacy of panobinostat in combination with established agents.
In the treatment of patients with multiple myeloma, disparities in care based on socioeconomic and demographic parameters affect survival outcomes, according to studies presented at the 2014 American Society of Hematology meeting.